Although anti-CD19 achieved remarkable efficacy in B-cell lymphoma [11–13], a large proportion of patients experienced progressive disease partially as a result of tumor antigen loss [30]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.